[go: up one dir, main page]

NO20023645L - Selektiv krystallisering av natrium 3-pyridyl-1- hydroksyetyliden-1,1-bisfosfonsyre som hemipentahydrat ellermonohydrat - Google Patents

Selektiv krystallisering av natrium 3-pyridyl-1- hydroksyetyliden-1,1-bisfosfonsyre som hemipentahydrat ellermonohydrat

Info

Publication number
NO20023645L
NO20023645L NO20023645A NO20023645A NO20023645L NO 20023645 L NO20023645 L NO 20023645L NO 20023645 A NO20023645 A NO 20023645A NO 20023645 A NO20023645 A NO 20023645A NO 20023645 L NO20023645 L NO 20023645L
Authority
NO
Norway
Prior art keywords
hemipentahydrate
hydroxyethylidene
monohydrate
pyridyl
sodium
Prior art date
Application number
NO20023645A
Other languages
English (en)
Other versions
NO329923B1 (no
NO20023645D0 (no
Inventor
Frederick Dana Cazer
Gregory Eugene Parry
Dennis Michael Billings
Nancy Lee Redman-Furey
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22656866&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20023645(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of NO20023645D0 publication Critical patent/NO20023645D0/no
Publication of NO20023645L publication Critical patent/NO20023645L/no
Publication of NO329923B1 publication Critical patent/NO329923B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20023645A 2000-02-01 2002-07-31 Selektiv krystallisering av natrium 3-pyridyl-1-hydroksyetyliden-1,1-bisfosfonsyre som hemipentahydrat eller monohydrat NO329923B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17950500P 2000-02-01 2000-02-01
PCT/US2001/003336 WO2001056983A2 (en) 2000-02-01 2001-02-01 Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate

Publications (3)

Publication Number Publication Date
NO20023645D0 NO20023645D0 (no) 2002-07-31
NO20023645L true NO20023645L (no) 2002-10-01
NO329923B1 NO329923B1 (no) 2011-01-24

Family

ID=22656866

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20023645A NO329923B1 (no) 2000-02-01 2002-07-31 Selektiv krystallisering av natrium 3-pyridyl-1-hydroksyetyliden-1,1-bisfosfonsyre som hemipentahydrat eller monohydrat

Country Status (33)

Country Link
US (1) US6410520B2 (no)
EP (1) EP1252170B2 (no)
JP (5) JP2003521532A (no)
KR (1) KR100549038B1 (no)
CN (1) CN1183148C (no)
AR (1) AR030187A1 (no)
AT (1) ATE273984T1 (no)
AU (1) AU784307B2 (no)
BR (1) BRPI0107921B8 (no)
CA (1) CA2399976C (no)
CO (1) CO5271720A1 (no)
CZ (1) CZ303400B6 (no)
DE (1) DE60104978T3 (no)
DK (1) DK1252170T4 (no)
ES (1) ES2225481T5 (no)
HK (1) HK1051046B (no)
HU (1) HU230494B1 (no)
IL (2) IL150511A0 (no)
MA (1) MA25654A1 (no)
MX (1) MXPA02007417A (no)
MY (1) MY119968A (no)
NO (1) NO329923B1 (no)
NZ (1) NZ519966A (no)
PE (1) PE20011061A1 (no)
PL (1) PL207589B1 (no)
PT (1) PT1252170E (no)
RU (1) RU2236415C2 (no)
SA (1) SA01220066B1 (no)
SK (1) SK287884B6 (no)
TR (1) TR200402435T4 (no)
TW (1) TWI310769B (no)
WO (1) WO2001056983A2 (no)
ZA (1) ZA200205090B (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410520B2 (en) * 2000-02-01 2002-06-25 The Procter & Gamble Company Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1, 1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate
EP1923052A1 (en) 2002-04-11 2008-05-21 Teva Pharmaceutical Industries Ltd Novel polymorphs and pseudopolymorphs of risedronate sodium
HRP20041051A2 (en) * 2002-04-11 2005-02-28 Teva Pharmaceutical Industries Ltd. Novel polymorphs and pseudopolymorphs of risedronate sodium
CZ20023574A3 (en) 2002-10-25 2004-04-14 Léčiva, A.S. New crystalline form of the sodium salt of 3-pyridyl-1-hydroxyehtylidene-1,1-bisphosphonic acid
DE602004015407D1 (de) * 2003-01-17 2008-09-11 Teva Pharma Verfahren zur reduzierung des eisengehalts bei risedronat natrium
HUP0300227A2 (hu) * 2003-01-28 2004-09-28 Richter Gedeon Vegyészeti Gyár Rt. Eljárás nagy tisztaságú 2-szubsztituált -1-(hidroxi-etilidén)-1,1-biszfoszfonsavak és sóik előállítására
CN100439377C (zh) * 2003-07-30 2008-12-03 宝洁公司 控制利塞膦酸盐晶体结构的方法
CZ298639B6 (cs) * 2004-02-05 2007-12-05 Zentiva, A. S. Krystalická forma risedronátu monosodného
PL213481B1 (pl) * 2004-02-26 2013-03-29 Zentiva As Amorficzne postaci rizedronianu monosodowego, sposób wytwarzania i preparat farmaceutyczny
WO2005107714A2 (en) * 2004-05-05 2005-11-17 Alkermes Controlled Therapeutics, Inc. Method of forming microparticles that include a bisphosphonate and a polymer
ES2921141T3 (es) 2004-05-24 2022-08-18 Theramex Hq Uk Ltd Forma farmacéutica oral sólida entérica de un bisfosfonato que contiene un agente quelante
US8012949B2 (en) * 2004-10-08 2011-09-06 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
WO2006039721A2 (en) * 2004-10-08 2006-04-13 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
WO2006051553A1 (en) * 2004-11-09 2006-05-18 Jubilant Organosys Limited Process for preparing a pure polymorphic form of 3-pyridyl-1-hydroxyethylidine-1,1-bisphosphonic acid sodium salt
PL199215B1 (pl) * 2004-12-28 2008-08-29 Politechnika Gdanska Sposób wytwarzania kwasu [1-hydroksy-2-(3-pirydylo)etylidenobisfosfonowego] oraz jego soli monosodowej dwu i pół wodnej
ES2324015T1 (es) * 2005-05-06 2009-07-29 Medichem, S.A. Proceso de sintesis de acidos bisfosfonicos geminales o de sus sales farmaceuticamente aceptables o de sus hidratos.
WO2006134603A1 (en) 2005-06-13 2006-12-21 Jubilant Organosys Limited Process for producing bisphosphonic acids and forms thereof
AR054673A1 (es) * 2005-07-28 2007-07-11 Gador Sa Una forma cristalina del acido zoledronico, un proceso para su obtencion y la composicion farmaceutica que la comprende
GB0519891D0 (en) * 2005-09-30 2005-11-09 Pliva Hrvatska D O O Pharmaceutically acceptable salts and hydrates
WO2007042048A2 (en) * 2005-10-11 2007-04-19 Sandoz A/S Method for preparing crystalline sodium risedronate
EP1775302A1 (en) * 2005-10-11 2007-04-18 Sandoz A/S Method for preparing crystalline sodium risedronate
EP1981896B1 (en) * 2006-01-20 2013-03-13 Aurobindo Pharma Limited An improved process for the preparation of risedronate sodium hemi-pentahydrate
JP2009530414A (ja) * 2006-03-17 2009-08-27 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ ビスホスホネート化合物及び方法
JP5354858B2 (ja) * 2006-05-09 2013-11-27 株式会社Ａｄｅｋａ スルホンアミド化合物の金属塩を含有するポリエステル樹脂組成物
KR20090005206A (ko) 2006-05-11 2009-01-12 인드-스위프트 래버러토리즈 리미티드 순수한 리세드론산 또는 염의 제조 방법
EP2041148A1 (en) * 2006-07-03 2009-04-01 Generics Ýuk¨Limited Novel process for the preparation of bisphosphonic acids
WO2008065542A2 (en) * 2006-09-22 2008-06-05 Orchid Chemicals & Pharmaceuticals Ltd. An improved process for the preparation of risedronate sodium
WO2008044245A2 (en) * 2006-10-10 2008-04-17 Matrix Laboratories Ltd A process for the preparation of risedronate sodium hemipentahydrate
KR100828705B1 (ko) 2006-12-04 2008-05-09 씨제이제일제당 (주) 리세드론산 나트륨 수화물의 제조방법
KR100775440B1 (ko) * 2006-12-20 2007-11-12 동우신테크 주식회사 리세드로네이트 나트륨 헤미펜타히드레이트의 제조방법
KR100798855B1 (ko) * 2007-02-14 2008-01-28 주식회사 엔지켐 리세드론산 나트륨 헤미펜타하이드레이트의 제조방법
KR100812528B1 (ko) * 2007-04-12 2008-03-12 보령제약 주식회사 리세드로네이트 나트륨염의 헤미펜타히드레이트의 선택적결정화방법
WO2008152518A2 (en) * 2007-05-16 2008-12-18 Actavis Group Ptc Ehf Process for the preparation of risedronic acid or risedronate sodium
WO2009050731A2 (en) * 2007-06-20 2009-04-23 Alkem Laboratories Ltd Novel process for preparing risedronic acid
DE102007030370A1 (de) 2007-06-29 2009-01-02 Ratiopharm Gmbh Essigsäure-Solvate von Risedronat, Polymorph hiervon, deren Herstellung und Verwendung sowie pharmazeutische Zusammensetzung, enthaltend diese
KR100925835B1 (ko) * 2007-12-07 2009-11-06 동우신테크 주식회사 리세드로네이트 나트륨 무수물 및 수화물의 제조방법
KR101010062B1 (ko) 2008-04-11 2011-01-21 주식회사 대희화학 증발 결정화를 이용한 결정상 리세드로네이트 모노소듐모노하이드레이트의 제조방법
US8629178B2 (en) * 2009-11-03 2014-01-14 Li Liu Sodium tanshinone IIA sulfonate hydrate and preparation method and use thereof
TWI702220B (zh) * 2015-07-08 2020-08-21 日商第一三共股份有限公司 吡啶化合物
JP7028243B2 (ja) 2017-06-06 2022-03-02 三菱ケミカル株式会社 ポリオルガノシロキサン含有グラフト共重合体、熱可塑性樹脂組成物及び成形体

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2534391C2 (de) 1975-08-01 1983-01-13 Henkel KGaA, 4000 Düsseldorf 1-Hydroxy-3-aminoalkan-1,1-diphosphonsäuren
US4447256A (en) 1977-07-20 1984-05-08 Nissan Chemical Industries, Ltd. N-(Unsubstituted or substituted pyridyl)aminomethylene-diphosphonic acids, herbicidal compositions containing same, their use for herbicides, and process for preparing same
DE2745083C2 (de) 1977-10-07 1985-05-02 Henkel KGaA, 4000 Düsseldorf Hydroxydiphosphonsäuren und Verfahren zu deren Herstellung
US4330537A (en) 1977-12-07 1982-05-18 The Procter & Gamble Company Compositions for inhibiting mobilization of calcium phosphate in animal tissue
JPS5598193A (en) 1979-01-22 1980-07-25 Nissan Chem Ind Ltd Methylenediphosphonic acid derivative and herbicide comprising it as active constituent
DE2943498C2 (de) 1979-10-27 1983-01-27 Henkel KGaA, 4000 Düsseldorf Verfahren zur Herstellung von 3-Amino-1-hydroxypropan-1,1-diphosphonsäure
DE3016289A1 (de) 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
US4304734A (en) 1980-10-16 1981-12-08 Vysoka Skola Chemicko-Technologicka 6-Amino-1-hydroxyhexylidene diphosphonic acid, salts and a process for production thereof
DE3151038A1 (de) 1981-12-23 1983-07-28 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von 3-amino-1-hydroxypropan-1,1-diphosphonsaeure
IT1201087B (it) 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
DE3428524A1 (de) * 1984-08-02 1986-02-13 Boehringer Mannheim Gmbh, 6800 Mannheim Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
IT1196315B (it) 1984-10-29 1988-11-16 Gentili Ist Spa Procedimento per la preparazione di acidi difosfonici
IL77243A (en) 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
PH27078A (en) * 1984-12-21 1993-02-01 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonates
IT1187750B (it) 1985-10-15 1987-12-23 Eurand Spa Procedimento per la preparazione di compresse,anche a rilascio prolungato,di iscsorbide-5-mononitrato stabilizzato e formulazioni cosi' ottenute
DE3540150A1 (de) 1985-11-13 1987-05-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
GB8531071D0 (en) 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
DE3773716D1 (de) 1986-03-24 1991-11-21 Nippon Kayaku Kk Verfahren zur herstellung von monosodiumsalz und dessen monohydrat von 1-beta-d-arabinofuranosylcytosin-5'stearylphosphat und diese enthaltende pharmazeutische zusammensetzung.
DE3623397A1 (de) 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3626058A1 (de) 1986-08-01 1988-02-11 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE10199052I1 (de) 1986-11-21 2002-01-10 Novartis Ag Neue substituierte Alkandiphosphonsaeuren
DE3700772A1 (de) 1987-01-13 1988-07-21 Inst Khim Kinetiki I Gorenija Verfahren zur herstellung von i-funktionellsubstituierten alkyliden-i,i-diphosphonsaeuren und deren gemischen
US5091525A (en) 1987-10-07 1992-02-25 Eli Lilly And Company Monohydrate and DMF solvates of a new carbacephem antibiotic
US5035898A (en) 1987-11-27 1991-07-30 Schering Corporation Potassium/magnesium supplement
US5110807A (en) 1988-12-01 1992-05-05 Ciba-Geigy Corporation Araliphatylaminoalkanediphosphonic acids
DE3822650A1 (de) 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3917153A1 (de) 1989-05-26 1990-11-29 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
MX21453A (es) 1989-07-07 1994-01-31 Ciba Geigy Ag Preparaciones farmaceuticas que se administran en forma topica.
MX21452A (es) 1989-07-07 1994-01-31 Ciba Geigy Ag Preparaciones farmaceuticas que se administran en forma topica.
TW208013B (no) 1990-03-01 1993-06-21 Daiichi Co Ltd
EP0544812B1 (en) 1990-08-21 1995-04-05 The Upjohn Company Bisphosphonic acid derivatives as anti-arthritic agents
US5039819A (en) 1990-09-18 1991-08-13 Merck & Co., Inc. Diphosphonate intermediate for preparing an antihypercalcemic agent
IT1246992B (it) 1991-01-08 1994-12-12 Gentili Ist Spa Procedimento per la preparazione di acidi difosfonici e loro sali
DK58291D0 (da) 1991-04-02 1991-04-02 Novo Nordisk As Krystalinsk stof og dets fremstilling
CZ282760B6 (cs) * 1991-11-22 1997-09-17 Procter And Gamble Pharmaceuticals, Inc. Risedronátové prostředky se zpožděným uvolňováním
SE501389C2 (sv) 1992-04-24 1995-01-30 Leiras Oy Farmaceutiskt preparat och förfarande för dess framställning
US5317015A (en) 1992-05-01 1994-05-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. Azacyclic bisphosphonates as anticholesterolemic agents
EP0647649B1 (en) 1992-06-23 1998-11-11 Yamanouchi Pharmaceutical Co. Ltd. Novel crystal of monohydrate of heterocyclic bis(phosphonic acid) derivative
FR2694558B1 (fr) * 1992-08-05 1994-10-28 Sanofi Elf Monohydrate du sel disodique de l'acide 4-chlorophénylthiométhylène bisphosphonique, sa préparation, les compositions pharmaceutiques en contenant.
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
SK135195A3 (en) 1993-04-28 1996-03-06 Pfizer Crystaline spirostalnylglycosidal, its monohydrate pharmaceutical agent on its base and method of production of crystaline steroid glycoside
US5510517A (en) 1993-08-25 1996-04-23 Merck & Co., Inc. Process for producing N-amino-1-hydroxy-alkylidene-1,1-bisphosphonic acids
TW257765B (no) * 1993-08-25 1995-09-21 Merck & Co Inc
US5580977A (en) 1995-03-01 1996-12-03 Eli Lilly And Company Process for preparing loracarbef monohydrate
TW393488B (en) 1995-04-20 2000-06-11 Merck & Co Inc Process for making 1-hydrox-ybisphosphonates
US5656288A (en) * 1995-06-08 1997-08-12 Sanofi Winthrop, Inc. Stable pharmaceutical compositions containing tiludronate hydrates and process for producing the pharmaceutical compositions
JP2000504718A (ja) 1996-02-14 2000-04-18 バインダーマン，イザク 骨吸収を予防するための局所用ビスホスホネート
ATE256456T1 (de) 1996-05-17 2004-01-15 Merck & Co Inc Biphosphonat-formulierung mit brausewirkung
US5730715A (en) 1996-06-14 1998-03-24 Becton Dickinson And Company Method for the iontophoretic administration of bisphosphonates
KR100192215B1 (ko) 1996-09-03 1999-06-15 강재헌 3-아미노-1-히드록시프로판-1,1-디포스폰산의 제조방법
CA2293815C (en) * 1997-06-11 2004-06-29 The Procter & Gamble Company Film-coated tablet for improved upper gastrointestinal tract safety
DE69827079T2 (de) * 1997-07-15 2005-09-08 Gador S.A. Kristalline Form von N,N-dimethyl-3-amino-1-hydroxypropan-1,1-Diphosphonsäure Mononatriumsalz Monohydrat und ein Verfahren zu ihrer Herstellung
US6432932B1 (en) * 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
WO1999066945A1 (en) * 1998-06-24 1999-12-29 Merck & Co., Inc. Compositions and methods for inhibiting bone resorption
IL142515A0 (en) * 1999-12-20 2002-03-10 Merck & Co Inc Pharmaceutical kit
US6410520B2 (en) * 2000-02-01 2002-06-25 The Procter & Gamble Company Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1, 1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate

Also Published As

Publication number Publication date
AU3473601A (en) 2001-08-14
SA01220066B1 (ar) 2006-11-25
PT1252170E (pt) 2004-12-31
TWI310769B (en) 2009-06-11
JP5405343B2 (ja) 2014-02-05
DE60104978D1 (de) 2004-09-23
PL207589B1 (pl) 2011-01-31
TR200402435T4 (tr) 2004-12-21
JP2016028083A (ja) 2016-02-25
IL150511A0 (en) 2003-02-12
SK287884B6 (sk) 2012-02-03
AR030187A1 (es) 2003-08-13
JP2014208716A (ja) 2014-11-06
JP2003521532A (ja) 2003-07-15
KR20020071976A (ko) 2002-09-13
HUP0204203A2 (en) 2003-05-28
BRPI0107921B1 (pt) 2020-11-10
JP5900553B2 (ja) 2016-04-06
EP1252170B2 (en) 2013-11-06
KR100549038B1 (ko) 2006-02-02
DE60104978T2 (de) 2005-08-18
JP2012255013A (ja) 2012-12-27
WO2001056983A2 (en) 2001-08-09
HK1051046B (en) 2005-04-29
HU230494B1 (hu) 2016-09-28
BR0107921A (pt) 2002-10-22
NO329923B1 (no) 2011-01-24
PL357097A1 (en) 2004-07-12
US6410520B2 (en) 2002-06-25
EP1252170A2 (en) 2002-10-30
DE60104978T3 (de) 2014-04-03
RU2236415C2 (ru) 2004-09-20
DK1252170T3 (da) 2004-12-13
CA2399976C (en) 2007-03-27
EP1252170B1 (en) 2004-08-18
JP5859930B2 (ja) 2016-02-16
CA2399976A1 (en) 2001-08-09
DK1252170T4 (da) 2014-01-20
CZ303400B6 (cs) 2012-08-29
ZA200205090B (en) 2003-04-30
HK1051046A1 (en) 2003-07-18
JP2010159264A (ja) 2010-07-22
MXPA02007417A (es) 2002-12-09
MY119968A (en) 2005-08-30
CN1396926A (zh) 2003-02-12
PE20011061A1 (es) 2001-11-20
US20020002282A1 (en) 2002-01-03
MA25654A1 (fr) 2002-12-31
ATE273984T1 (de) 2004-09-15
WO2001056983A3 (en) 2002-03-07
NO20023645D0 (no) 2002-07-31
NZ519966A (en) 2004-03-26
RU2002123369A (ru) 2004-01-10
ES2225481T5 (es) 2014-02-19
IL150511A (en) 2006-12-10
CN1183148C (zh) 2005-01-05
ES2225481T3 (es) 2005-03-16
HUP0204203A3 (en) 2005-02-28
SK11002002A3 (sk) 2003-02-04
CO5271720A1 (es) 2003-04-30
BRPI0107921B8 (pt) 2021-05-25
AU784307B2 (en) 2006-03-09

Similar Documents

Publication Publication Date Title
NO20023645L (no) Selektiv krystallisering av natrium 3-pyridyl-1- hydroksyetyliden-1,1-bisfosfonsyre som hemipentahydrat ellermonohydrat
NO20005450L (no) Imidazopyridinderivater som inhiberer magesyresekresjon
EE200300001A (et) Perindopriili tert-butüülamiinsoola kristallilinealfa-vorm
NO20025525L (no) Substituerte pyrrolpyridinonderivater, brukbare som fosfordiesterase-inhibitorer
DK1456206T3 (da) Azaindolylalkylaminderivater som 5-hydroxytryptamin-6-ligander
NO20042575L (no) Fremgangsmate for vat granulering av azithromycin
NO20032613D0 (no) Farmasöytisk sammensetning som har en forbedret vannopplöselighet
DK1355900T3 (da) Heterocyclylalkylindol- eller -azaindolforbindelser som 5-hydroxytryptamin-6-ligander
DK1455779T3 (da) Indolylalkylaminderivater som 5-hydroxytryptamin-6-ligander
NO20053730D0 (no) Pyridinderivater anvendelig for hemming av natrium/kalsium-utbyttingssystem
DK1353930T3 (da) Fremgangsmåde til fremstilling af N-phosphonomethyliminodieddikesyre
NO20043084L (no) 3-fenyl-2-arylalkyltiopropionsyre derivater som selektive agnoister av PPAR-ALPHA
NO20042057L (no) Fosfonsyreforbindelser som inhibitorer av serinproteaser
NO20025703D0 (no) Fremgangsmåte for fremstilling av vannfritt natriumperklorat
NO20044629L (no) Fremgangsmate til fremstilling av sure salter av gemifloksasin.
ITRM20010309A0 (it) Procedimento per la produzione di composti perfluoro-organici mediante florurazione elettrochimica.
NO20035138D0 (no) Fremgangsmåte til fremstilling av amorft natriumsilastatin
AU2002338038A1 (en) Aqueous ecabet sodium solution preparation
NO20040423L (no) Salter av substituerte 1,2,3,4-tetrahydroisokinolin-2-karboksylsyrederivater.
ATE297939T1 (de) Herstellung von kristallinen polymorphen von fosinopril natrium
IT1303734B1 (it) Forma cristallina del diclofenac sale sodico.
NO994261D0 (no) FremgangsmÕte for fremstilling av trovafloxacinsyresalter
ZA200405252B (en) 6-O-Acyl ketolide derivatives of erythromycine useful as antibacterials.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees
MK1K Patent expired